Brian T. Hopkins

Biogen (United States) — United States

Medicine · Health Sciences

15h-index815citations31works11.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(13), Chemical Synthesis and Analysis(9), Synthetic Organic Chemistry Methods(8), Chronic Myeloid Leukemia Treatments(5), Immunodeficiency and Autoimmune Disorders(5)

Publications31 total

Involvement of Btk in Cardiovascular Disease and Its Therapeutic Targeting
Circulation·2026
Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis
Journal of Medicinal Chemistry·2024· 15 citedOpen Access
The Discovery of 7-Isopropoxy-2-(1-methyl-2-oxabicyclo[2.1.1]hexan-4-yl)-<i>N</i>-(6-methylpyrazolo[1,5-<i>a</i>]pyrimidin-3-yl)imidazo[1,2-<i>a</i>]pyrimidine-6-carboxamide (BIO-7488), a Potent, Selective, and CNS-Penetrant IRAK4 Inhibitor for the Treatment of Ischemic Stroke
Journal of Medicinal Chemistry·2024· 20 citedOpen Access
Discovery of structural diverse reversible BTK inhibitors utilized to develop a novel in vivo CD69 and CD86 PK/PD mouse model
Bioorganic & Medicinal Chemistry Letters·2022· 2 citedOpen Access
Corrigendum to “Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors” [Bioorg. Med. Chem. Lett. 60 (2022) 128549]
Bioorganic & Medicinal Chemistry Letters·2022
BTK inhibition limits B-cell–T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy
Acta Neuropathologica·2022· 64 citedOpen Access
Discovery of Phospholipase D Inhibitors with Improved Drug-like Properties and Central Nervous System Penetrance
ACS Medicinal Chemistry Letters·2022· 12 citedOpen Access
Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors
Bioorganic & Medicinal Chemistry Letters·2022· 8 citedOpen Access
Sulfone Displacement Approach for Large-Scale Synthesis of 4-Chloro-<i>N</i>-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-amine
Organic Process Research & Development·2021· 6 cited
Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis
Journal of Medicinal Chemistry·2021· 37 citedOpen Access
Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton’s tyrosine kinase inhibitors
Bioorganic & Medicinal Chemistry·2021· 11 citedOpen Access
Next‐generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells
Clinical & Translational Immunology·2021· 24 citedOpen Access
Discovery of BIIB068: A Selective, Potent, Reversible Bruton’s Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases
Journal of Medicinal Chemistry·2020· 36 citedOpen Access
Process Development and Large-Scale Synthesis of BTK Inhibitor BIIB068
Organic Process Research & Development·2020· 7 cited
Discovery and Process Development of BIIB068: A Reversible Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Autoimmune Diseases
ACS symposium series·2020
Utilization of Cyclic Amides as Masked Aldehyde Equivalents in Reductive Amination Reactions
The Journal of Organic Chemistry·2019· 8 cited
Optimization of novel reversible Bruton’s tyrosine kinase inhibitors identified using Tethering-fragment-based screens
Bioorganic & Medicinal Chemistry·2019· 15 citedOpen Access
CDK12-mediated transcriptional regulation of noncanonical NF-κB components is essential for signaling
Science Signaling·2018· 38 cited
Abstract C186: SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation
Molecular Cancer Therapeutics·2015· 24 cited
Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases
Protein Science·2010· 148 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Anthony G. M. Barrett(10), Bin Ma(8), Claire M. Metrick(8), Bekim Bajrami(7), Eris Bame(7), Tonika Bohnert(7), Hao Tang(6), Michaël Mingueneau(6), Isaac E. Marx(6), D.J. Marcotte(5), Patrick Cullen(5), Tracy J. Jenkins(5), Paramasivam Murugan(5), Joseph C. Santoro(5), Elisabeth Mertsching(4), Laura Silvian(4), Chungang Gu(4), Marc Hoemberger(4), Kevin L. Otipoby(4), Urjana Poreci(4)